These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19515784)

  • 1. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
    Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
    Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
    AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.
    Knops E; Däumer M; Awerkiew S; Kartashev V; Schülter E; Kutsev S; Brakier-Gingras L; Kaiser R; Pfister H; Verheyen J
    J Antimicrob Chemother; 2010 Jul; 65(7):1472-6. PubMed ID: 20430786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
    Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
    Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Immunodeficiency Virus Gag and protease: partners in resistance.
    Fun A; Wensing AM; Verheyen J; Nijhuis M
    Retrovirology; 2012 Aug; 9():63. PubMed ID: 22867298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
    Kolli M; Stawiski E; Chappey C; Schiffer CA
    J Virol; 2009 Nov; 83(21):11027-42. PubMed ID: 19706699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
    Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
    AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
    Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
    Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.